Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system xc- over the vesicular glutamate transporter

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2680-2683

  Etoga, Jean Louis G ^a   Ahmed, S Kaleem ^a   Patel, Sarjubhai ^a   Bridges, Richard J ^a   Thompson, Charles M ^a,b  

^a UNIVERSITY OF MONTANA   (United States)

^b ATERIS Technologies LLC   (United States)

Author keywords

Amino acid analog; Glutamate; Inhibitor; Sulfonic acid; System xc ; VGLUT

Indexed keywords

2 THIOPHENEGLYCINE 5 SULFONIC ACID; 3 AMINO 4 METHYLTHIOPHENE 2 CARBOXYLIC ACID; 3 METHYL 5 AMINOTHIOPHENE 2,4 DICARBOXYLIC ACID; 4 (4' CARBOXYPHENYL)PHENYLGLYCINE; 4 CARBOXYPHENYLGLYCINE; AMINO ACID DERIVATIVE; CYSTEINE; GLUTAMIC ACID; GLYCINE DERIVATIVE; NEUROTRANSMITTER; SULFONIC ACID DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; INFRARED SPECTROSCOPY; MASS SPECTROMETER; NEUROTRANSMISSION; PROTON NUCLEAR MAGNETIC RESONANCE; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION;

GLYCINE; MOLECULAR CONFORMATION; SULFONIC ACIDS; VESICULAR GLUTAMATE TRANSPORT PROTEINS;

EID: 77950182231     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.020     Document Type: Article

References (35)

1. Byrnes K.R., Loane D.J., and Faden A.I. Neurotherapeutics 6 (2009) 94
2. Choi D.W., and Rothman S.M. Annu. Rev. Neurosci. 13 (1990) 171
3. Balazs R., Bridges R.J., and Cotman C.W. Excitatory Amino Acid Transmission in Health and Disease (2006), Oxford University Press, New York
4. Jane D.E., Lodge D., and Collingridge G.L. Neuropharmacology 56 (2009) 90
5. Swanson G.T., and Sakai R. Prog. Mol. Subcell Biol. 46 (2009) 123
6. Shigeri Y., and Shimamoto K. Nippon Yakurigaku Zasshi 122 (2003) 253
7. Reis H.J., Guatimosim C., Paquet M., Santos M., Ribeiro F.M., Kummer A., Schenatto G., Vsalgado J.V., Vieira L.B., Teixeira A.L., and Palotas A. Curr. Med. Chem. 16 (2009) 796
8. Bridges R.J., and Esslinger C.S. Pharmacol. Ther. 107 (2005) 271
9. 3H-l-glutamate (100 μM) and inhibitor (500 μM) were added. Each well was rinsed with HBHS (0 °C, 3×) and the cells treated with 1 mL 0.4 M NaOH for 24 h. Acetic acid (5 μL) was added to an aliquot (200 μL) and the radioactivity quantified versus background.
10. Domercq M., Sanchez-Gomez M.V., Sherwin C., Etxebarria E., Fern R., and Matute C. J. Immunol. 178 (2007) 6549
11. Burdo J., Dargusch R., and Schubert D. J. Histochem. Cytochem. 54 (2006) 549
12. - (2009), Springer, NY
13. Takamori S. Neurosci. Res. 55 (2006) 343
14. Moriyama Y., and Omote H. Biol. Pharm. Bull. 31 (2008) 1844
15. Carlson M.D., Kish P.E., and Ueda T. J. Neurochem. 53 (1989) 1889
16. Natale N.R., Magnusson K.R., and Nelson J.K. Curr. Top. Med. Chem. 6 (2006) 823
17. Warren B.A., Patel S.A., Nunn P.B., and Bridges R.J. Toxicol. Appl. Pharmacol. 200 (2004) 83
18. Bartlett, R.D. Ph.D. Thesis; The University of Montana, Missoula, MT, 1999.
19. Bartlett R.D., Esslinger C.S., Thompson C.M., and Bridges R.J. Neuropharmacology 37 (1998) 839
20. Carrigan C.N., Bartlett R.D., Esslinger C.S., Cybulski K.A., Tongcharoensirikul P., Bridges R.J., and Thompson C.M. J. Med. Chem. 45 (2002) 2260
21. Carrigan C.N., Esslinger C.S., Bartlett R.D., Bridges R.J., and Thompson C.M. Bioorg. Med. Chem. Lett. 9 (1999) 2607
22. Kish, P.E., Ueda, T. Methods Enzymol. 1989, 174, 9. Assays were initiated by the addition of 3H-glutamate ± inhibitors (0.01-5 mM) to the synaptic vesicles (approx. 0.1 mg protein). Rates of uptake were normalized to protein content.
23. Patel S.A., Nagy J.O., Bolstad E.D., Gerdes J.M., and Thompson C.M. Bioorg. Med. Chem. Lett. 17 (2007) 5125
24. Roseth S., Fykse E.M., and Fonnum F. J. Neurochem. 65 (1995) 96
25. Roseth S., Fykse E.M., and Fonnum F. Biochem. Pharmacol. 56 (1998) 1243
26. Thompson C.M., Davis E., Carrigan C.N., Cox H.D., Bridges R.J., and Gerdes J.M. Curr. Med. Chem. 12 (2005) 2041
27. Bridges R.J., Stanley M.S., Anderson M.W., Cotman C.W., and Chamberlin A.R. J. Med. Chem. 34 (1991) 717
28. Dunlop J., Fear A., and Griffiths R. NeuroReport 2 (1991) 377
29. 1H NMR and MS. The resultant hydantoins were hydrolyzed directly.
30. Chruma J.J., Liu L., Zhou W., and Breslow R. Bioorg. Med. Chem. 13 (2005) 5873
31. Nenajdenko V.G., Zakurdaev E.P., Prusov E.V., and Balenkova E.S. Russ. Chem. Bull. 53 (2004) 2866
32. Stalker R.A., Munsch T.E., Tran J.D., Nie X., Warmuth R., Beatty A., and Aakeröy C.B. Tetrahedron 58 (2002) 4837
33. Shanbhag V.M., and Martell A.E. Inorg. Chem. 29 (2002) 1023
34. 2: C, 30.37, H, 2.97, N, 5.90. Found: C, 30.51, H, 2.88, N, 5.94.
35. Sontheimer H. J. Neurochem. 105 (2008) 287